Process for the manufacture of a solid pharmaceutical composition for oral administration with 5-chloro-N ({(5-2-oxo-3- [4- (3-oxo-4-morpholinyl) -phenyl] -1,3-oxazolidin -5-yl} -methyl) -2-thiophenecarboxamide
Production of solid, orally administered pharmaceutical compositions (A) containing 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidin-5-yl)-methyl)-2-thiophene-carboxamide (I) in hydrophilized form comprises: (a) preparing granules containing (I) in hydrophilized form by wet granulation； and (b) converting the granules, optionally with suitable additives, into (A). Independent claims are included for: (1) the compositions (A) obtained by the process； and (2) solid, orally administered pharmaceutical compositions (A') containing (I) in hydrophilized form in general. ACTIVITY : Thrombolytic； Anticoagulant； Cardiant； Antianginal； Vasotropic； Cerebroprotective. MECHANISM OF ACTION : Coagulation factor Xa inhibitor.
